Losses, adjusted for pretax gains, came to $2.27 per share. The results fell short of Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of $2 per share. The biotechnology company posted revenue of $2.4 million in the period.
News
- Ultragenyx reports 4Q loss
- Bobby Alford, Baylor College of Medicine fixture, dies at 87
Dr. Bobby Alford, a Baylor College of Medicine fixture for more than half a century, died Tuesday. He was 87. Alford served in a number of leadership roles at Baylor, including dean of medicine and chairman of the department of otolaryngology. He grew the National Space Biomedical Research…
- Gonzaga receives approval to build science building
McCulloh said the idea was to develop programs beyond the "bedrock" disciplines currently offered at Gonzaga. In addition to mechanical and electrical engineering, students would be able to study bioinfomatics and materials science. "We're seeing information that is critical to research in…
- Sea Grant program getting $218K grant
Recent work in New Hampshire has focused on connecting local businesses with university research in a range of topics, including aquaculture, marine biotechnology, seafood processing, and the development of marine products. President Donald Trump's Fiscal Year 2019 budget request proposed…
- In crowded race to replace Lamar Smith, Cruz makes his pick plain
Mauro Garza of San Antonio was formerly director of grants and contracts management at the Southwest Foundation for Biomedical Research in San Antonio. In 2002, he founded Mauro M. Garza Enterprises Inc. and in 2010 founded Everett Holdings LLC. He has pointed to his experience running…